Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezivertinib in EGFR T790M+ NSCLC
NCT03812809Phase 2Completed
- Sponsor
- Beta Pharma
- Start
- Jul 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezivertinib in non-small cell lung cancer (NSCLC), sponsored by Beta Pharma. Started Jul 2019; status: completed.
02
Drugs
rezivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03812809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812809.